Pegulicianine Pregnancy and Breastfeeding Warnings
Brand names: Lumisight
Pegulicianine Pregnancy Warnings
The manufacturer makes no recommendation regarding use during pregnancy.
AU TGA pregnancy category: Not Assigned
US FDA pregnancy category: Not Assigned
-Risk summary: No data are available on the use of this drug in pregnant women to inform a drug-related risk.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Pegulicianine Breastfeeding Warnings
Benefit should outweigh risk.
Excreted into human milk: Unknown
Excreted into animal milk: Unknown
Comments:
-There is no information regarding this drug or metabolites on the presence in human milk, the effects on a breastfed infant, or effects on milk production.
-Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for this medication as well as any potential adverse effects on the breastfed infant from this drug or the underlying maternal condition.
References for pregnancy information
- (2024) "Product Information. Lumisight (pegulicianine)." Lumicell, Inc.
References for breastfeeding information
- (2024) "Product Information. Lumisight (pegulicianine)." Lumicell, Inc.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
